Aminoguanidine impedes human pancreatic tumor growth and metastasis development in nude mice by Mohamad, Nora Alicia et al.
www.wjgnet.com
 ORIGINAL ARTICLES
Aminoguanidine impedes human pancreatic tumor growth 
and metastasis development in nude mice
Nora A Mohamad, Graciela P Cricco, Lorena A Sambuco, Máximo Croci, Vanina A Medina, Alicia S Gutiérrez, 
Rosa M Bergoc, Elena S Rivera, Gabriela A Martín
Nora A Mohamad, Graciela P Cricco, Lorena A Sambuco, 
Vanina A Medina, Alicia S Gutiérrez, Rosa M Bergoc, Elena 
S Rivera, Gabriela A Martín, Laboratory of Radioisotopes, 
School of Pharmacy and Biochemistry, University of Buenos 
Aires, Junín 954 (C1113AAB), Buenos Aires, Argentina
Máximo Croci, Institute of Immunooncology Dr. Ernesto 
Crescenti, Av. Córdoba 3200 (C1187AAS), Buenos Aires, 
Argentina
Rosa M Bergoc, Gabriela A Martín, National Research 
Council (CONICET), Av. Rivadavia 1917 (C1033AAJ), Buenos 
Aires, Argentina
Author contributions: Mohamad NA and Gutiérrez AS performed 
the ex vivo experiments; Cricco GP and Sambuco LA performed 
the in vivo experiments; Bergoc RM and Croci M performed the 
microscopical observation; Cricco GP and Martín GA designed 
the study; Rivera ES and Medina VA were involved in editing 
the manuscript and in critical review; Martín GA and Rivera ES 
participated in acquisition of funding; Mohamad NA, Cricco GP 
and Martín GA analyzed the data and wrote the manuscript.
Supported by Grants from University of Buenos Aires (B098 
and B112)
Correspondence to: Dr. Gabriela A Martín, Laboratory 
of Radioisotopes, School of Pharmacy and Biochemistry, 
University of Buenos Aires, Junín 954 (C1113AAB), Buenos 
Aires, Argentina. gamartin@ffyb.uba.ar
Telephone: +54-11-49648277-34  Fax: +54-11-49648277-31
Received: September 20, 2008       Revised: January 17, 2009
Accepted: January 24, 2009
Published online: March 7, 2009
Abstract
AIM: To study the action of aminoguanidine on 
pancreatic cancer xenografts in relation to cell 
proliferation, apoptosis, redox status and vascularization.
METHODS: Xenografts of PANC-1 cells were developed 
in nude mice. The animals were separated into two 
groups: control and aminoguanidine treated. Tumor 
growth, survival and appearance of metastases were 
determined in vivo  in both groups. Tumors were excised 
and ex vivo  histochemical studies were performed. Cell 
growth was assessed by Ki-67 expression. Apoptosis 
was studied by intratumoral expression of B cell 
lymphoma-2 protein (Bcl-2) family proteins and Terminal 
deoxynucleotidyl transferase biotin-dUTP Nick End 
Labeling (Tunel). Redox status was evaluated by the 
expression of endothelial nitric oxide synthase (eNOS), 
catalase, copper-zinc superoxide dismutase (CuZnSOD), 
manganese superoxide dismutase (MnSOD) and 
glutathione peroxidase (GPx). Finally, vascularization 
was determined by Massons trichromic staining, and by 
VEGF and CD34 expression.
RESULTS: Tumor volumes after 32 d of treatment by 
aminoguanidine (AG) were significantly lower than 
in control mice (P  < 0.01). Median survival of AG 
mice was significantly greater than control animals 
(P  < 0.01). The appearance of both homolateral and 
contralateral palpable metastases was significantly 
delayed in AG group. Apoptotic cells, intratumoral 
vascularization (trichromic stain) and the expression of 
Ki-67, Bax, eNOS, CD34, VEGF, catalase, CuZnSOD and 
MnSOD were diminished in AG treated mice (P  < 0.01), 
while the expression of Bcl-2 and GPx did not change.
C O N C L U S I O N : T h e a n t i t u m o ra l a c t i o n o f 
aminoguanidine is associated with decreased cell 
proliferation, reduced angiogenesis, and reduced 
expression of antioxidant enzymes.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Pancreatic cancer is an aggressive carcinoma usually 
diagnosed at an advanced stage and shows a median 
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survival time of  only three months. Approximately half  
of  the cases are metastatic at the time of  diagnosis, 
while the remainder have locally advanced unresectable 
disease. To date, the only effective treatment is surgical 
therapy. Adjuvant chemo- and radiotherapy have not led 
to significant improvements in outcome[1]. 
Nitric oxide synthase (NOS) produce nitric oxide (NO) 
by the oxidation of  L-arginine. There are three known 
isoenzymes of  NOS: two constitutive forms [neuronal 
NOS (nNOS) and endothelial NOS (eNOS)] and one 
inducible form, inducible NOS (iNOS). Constitutive 
isoforms nNOS and eNOS respond to a calcium influx 
with a transient release of  NO[2]. On the other hand, iNOS 
always generates high quantities of  NO over a prolonged 
period[3]. This isoform is not only expressed in activated 
macrophages, usually infiltrating tumors, but also in various 
types of  malignant cells.
Nitric oxide is a highly diffusible, lipophilic free 
radical. Under certain pathological conditions, NO 
can combine with the superoxide anion (O2-) to form 
peroxynitrite (ONOO-), a potent reactive nitric oxide 
species that nitrates tyrosine residues in proteins and 
induces DNA damage and lipid peroxidation, leading to 
cell damage and often cell death. NO in cancer exhibits 
both a cytotoxic and a cytoprotective effect according to 
its concentration within the tumor microenvironment. 
Low levels of  NO produced by tumor cells themselves aid 
tumor progression, while the high level of  NO produced 
by tumor adjacent macrophages function as a tumor 
suppressor agent through the induction of  apoptosis[4-7].
Aminoguanidine, a nucleophilic hydrazine compound 
first synthesized more than 100 years ago, is an irreversible 
inhibitor of  iNOS, which also inhibits eNOS and nNOS 
at higher concentrations[8]. It has been shown in vivo to 
prevent disease states characterized by the pathological 
overproduction of  NO, such as diabetic complications[9], 
age-related arterial stiffening, cardiac hypertrophy[10] 
and also tumors (including cholangiocarcinoma[11] and 
gastric cancer[12]). These effects of  AG are exerted by 
modulating proliferation[12], apoptosis[12], angiogenesis[12], 
by the production of  free radicals[12] and by preventing the 
formation of  advanced glycation end products (AGEs)[13,14].
The human pancreatic ductal carcinoma, PANC-1, 
cells express constitutive eNOS. However, though it is 
the most commonly tumor associated synthase isoform, 
PANC-1 cells do not express iNOS[15].
Although the in vitro action of  NOS inhibitors 
has been extensively studied, little research has been 
undertaken as regards their in vivo effects on cancer 
growth. Therefore, the aim of  this work was to study 
the action of  the NOS inhibitor AG in PANC-1 human 
pancreatic cancer xenografts in nude mice in relation 
to tumor growth, angiogenesis and the expression of  
antioxidant enzymes.
MATERIALS AND METHODS
Xenografts in nude mice
PANC-1 cells (7 × 106) were collected by centrifugation 
and resuspended in 100 μL RPMI-1640 (GIBCO, Grand 
Island, New York, USA) to be inoculated in the dorsal 
flank of  each nude mouse (cepa N:NIH(S)-nu). When the 
tumors that developed reached a volume of  500 mm3 they 
were excised, cut into 27 mm3 pieces and grafted into the 
dorsal flank of  another nude mouse. Xenografted mice 
were separated in four groups (n = 7) and received daily 
doses of  AG (aminoguanidine hydrochloride, Sigma, Saint 
Louis, Missouri, USA) of  1, 2 or 4 mg/mL in drinking 
water. In vivo treatments began when the graft volumes 
reached 100-150 mm3. The control group was left without 
treatment. Tumor size was measured with a caliper three 
times a week and volume was calculated as [(mayor 
diameter + minor diameter)/4]3 × π4/3. Treatments 
lasted 32 d. Two-way ANOVA, Bonferroni post test and 
non linear fit of  tumor growth data were carried out by 
GraphPad Prism version 5.00™. All the experiments 
using mice were performed according to the NRC 
[National Research Council] Guide for the Care and Use 
of  Laboratory Animals, 7th ed, Washington DC, National 
Academy Press, 1996.
Survival
Mice bearing xenografts were divided into two groups 
(n = 7), AG (2 mg/mL in drinking water) and control, 
and followed until spontaneous death. Kaplan-Meier 
survival curves, median survival time of  each group 
and P value were obtained by GraphPad Prism™. 
Development of  palpable metastases was checked 
three times a week in both groups and the metastases 
were distinguished according to their location as either 
homolateral (those that appeared in the same flank as 
the xenograft) or contralateral (those that appeared in 
the opposite flank).
Histochemistry
At the end of  treatments, tumors were excised, fixed 
in 40 g/L formaldehyde in PBS (formalin), paraffin 
embedded and sliced into 3-μm thick sections for: 
(1) Tunel, using TdT-FragEL DNA Fragmentation 
Detec t ion Ki t (Ca lb iochem, a brand of  EMD 
Biosciences, La Jolla, California, USA) according to 
the manufacturer’s instructions. 3,3'-Diaminobenzidine 
tablets (DAB; Sigma) were used for staining and methyl 
green for counterstaining; (2) Immunohistochemical 
detection using antibodies against Ki-67 (1/50, Dako 
Cytomation, Carpinteria, California, USA), PCNA 
(1/100, Dako Cytomation), Bcl-2 (1/50, Santa Cruz 
Biotechnology, Santa Cruz, California, USA), Bax 
(1/50, Santa Cruz Biotechnology), eNOS (1/30 Sigma), 
VEGF (1/20, R&D Systems, USA), catalase (1/50, 
Sigma), CuZnSOD (1/50, Calbiochem), MnSOD (1/50, 
Calbiochem) and GPx (1/125, Stressgen, Ann Arbor, 
Michigan, USA). The appropriate secondary HRP-
conjugated antiserum was employed in each case. DAB 
tablets were used for staining and hematoxylin for 
counterstaining; (3) Tumor vascularization was assayed 
by means of  Masson trichrome and CD34 (1/50, Santa 
Cruz Biotechnology) staining; and (4) hematoxylin and 
eosin staining of  tumors and metastatic lymph nodes. 
Microscopic observations were performed using 
an Axiolab Karl Zeiss microscope by two independent 
observers. Photographs were taken with a Canon Power 
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Shot G5 digital camera and processed with Remote 
Capture 2.7 software. Metastatic lymph nodes, Tunel, 
trichrome stain and CD34 of  control mice were observed 
at 400 × and the remaining determinations at 630 ×. 
Microscopic observations were done in ten random 
fields and graded as percent of  positive cells. Positive 
nuclei were considered as positive cells for Tunel, Ki-67 
and PCNA, whereas diffuse positive cytoplasms were 
considered as positive cells for cytoplasmic proteins. 
Non parametric Mann Whitney tests on the percent of  
positive cells in control and AG groups were performed 
by GraphPad PrismTM. Peritumoral vascularity was 
assessed by screening trichrome stained sections at 50 × 
magnification to identify the largest vascular areas around 
the tumor. In these hot spots, individual vessel count was 
evaluated at 400 × magnification using an ocular grid. 
Intratumoral vascularity was evaluated on trichrome and 
CD34 stained slices, counting vessels inside the tumor 




Tumor growth: Animals were separated into four 
groups (control and 1, 2 and 4 mg/mL AG) to evaluate 
the effect of  AG on tumor growth. Mice were treated 
for 32 d when grafts volume reached 100-150 mm3. 
Tumor volumes were determined three times a week and 
finally referred to the initial volume for each treatment 
(Figure 1). AG (2 and 4 mg/mL) treatment significantly 
diminished the tumor growth rate. Tumor volumes of  
mice treated with AG 2 and 4 mg/mL from day 28 of  
treatment on were significantly different from tumors 
of  control animals (P < 0.01 for AG 2 and 4 mg/mL vs 
control, two way ANOVA and Bonferroni post test). 
In the same way, tumor volume doubling time of  mice 
treated with AG 2 or 4 mg/mL was significantly greater 
than the other groups (Table 1; P < 0.01 vs control and 
AG 1 mg/mL, Anova one way with Bonferroni post test).
Tumor histology: After excision of  tumors, xenografts 
usually showed macroscopic infiltration of  the dermis and 
abdominal muscular wall. Under microscopic observation, 
tumors presented undifferentiated adenocarcinoma cells, 
with high grade of  atypia, marked anisokaryosis and 
anisocytosis. Multinucleated cells and atypical mitoses (often 
tri- and tetrapolar mitoses) were frequently observed.
Survival and metastases: Two extra groups of  PANC-1 
xenografted animals (control and AG 2 mg/mL) were 
followed three times a week until spontaneous death. 
Kaplan-Meier survival curves (Figure 2A) were obtained 
for AG 2 mg/mL (dotted line) and control (solid line) 
groups. Median survival, i.e. the time at which survival 
percent equals 50%, of  AG treated animals (95 d) was 
significantly greater than that of  control mice (74 d; P < 0.01 
for AG vs control, log-rank test).
The same groups of  animals were checked for the 
development of  palpable metastases (concomitantly 
with survival studies) until the death of  the animals. 
The total number of  both homolateral and contralateral 
palpable metastases developed in each group (n = 7 
each group) was determined (Figure 2B). Appearance 
of  metastases was significantly delayed in AG treated 
mice. The medians of  appearance were 59 d for control 
homolateral metastases, 78 d for AG homolateral 
metastases and 92 d for AG contralateral metastases. 
The median for control contralateral metastases could 
not be determined since only two metastases appeared 
by the time of  death. Curves were significantly different.
Also, the number of  homolateral metastases per 
animal was lower in the AG group. The first control 
mouse died at 64 d; therefore, the mean number 
of  metastases per animal at 63 d was obtained and 
compared for each of  the four groups. Means, expressed 
as mean ± SD, were significantly different. The number 
of  homolateral metastases in the control (1.8 ± 0.4 per 
mouse) was significantly greater than in the other groups 
(0.3 ± 0.3 per mouse for control contralateral, 0.1 ± 0.1 
for AG homolateral and 0 for AG contralateral).
The metastases that developed were analyzed by 
microscopic observation after the mice died (Figure 3A). 
Both homolateral and contralateral metastases appeared 
mainly in the lymph nodes. The node architecture was 
only preserved in a few peripheral sections due to the 
considerable extent of  tumor infiltration. Infiltrating 
tumor cells showed the same histological characteristics 
as xenograft neoplastic cells (Figure 3B). This finding 
confirms the metastatic character of  the multiple masses 
found. 
Ex vivo studies
























Figure 1  Antitumor effect of AG in PANC-1 xenografted mice. Tumor 
volumes were determined and referred to the initial volume for each treatment. 
aP < 0.01 for AG 2 and 4 mg/mL vs control, two way ANOVA and Bonferroni 
post test.
Table 1  AG enlarges tumor volume doubling time (mean ± 
SD)
Treatment Doubling time (d)
Control  7.8 ± 0.3
AG 1 mg/mL  7.8 ± 0.3
AG 2 mg/mL 10.0 ± 0.5a
AG 4 mg/mL 11.1 ± 0.7a
Tumor volume doubling times were obtained by non linear fit of tumor 
growth rate (shown in Figure 1) to an exponential growth equation. aP < 0.01 
vs control and AG 1 mg/mL, ANOVA one way with Bonferroni post test.
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in xenografts was evaluated through the expression 
of  Ki-67[16] (Figure 3C and F). Apoptosis was studied 
in tumors by the Tunel assay (Figure 3D and G) and 
by the expression of  antiapoptotic protein Bcl-2 and 
proapoptotic Bax (Figure 3E and H).
Ki-67 expression, evaluated as percent of  positive cells 
(mean ± SD), was lower in tumors of  AG treated mice than 
in the control group (19 ± 11 vs 78 ± 10, P < 0.01, Mann 
Whitney test). Similar results were obtained by PCNA 
immunodetection, another proliferation marker.
The Tunel test showed a lower proportion of  
apoptotic cells in grafts of  animals which had received 
AG than the control group, (1 ± 1 vs 5 ± 1, P < 0.01, 
Mann Whitney test), evaluated as percent of  positive 
cells (mean ± SD). In the same way, the expression 
of  Bax, evaluated as percent of  positive cells (mean ± 
SD), was significantly lower in tumors of  AG treated 
animals than in control animals (17 ± 13 vs 88 ± 11, 
P < 0.01, Mann Whitney test). Lastly, Bcl-2 expression 
was not altered by AG treatment (20 ± 10 vs 15 ± 9, 
AG vs control). These results, therefore, indicate an 
antiapoptotic effect of  AG in xenografts.
Angiogenesis: Angiogenesis is essential for the growth, 
invasion and metastasis of  a tumor. eNOS has been 
shown to participate in tumor progression by promoting 
angiogenesis[17,18]. Vascular endothelial growth factor 
(VEGF), a potent endothelial cell mitogen and vascular 
permeability factor, is mainly implicated in tumor growth 
via the stimulation of  NO production[6,18]. To evaluate 
tumor angiogenesis in PANC-1 xenografts, eNOS and 
VEGF expressions were assayed, as well as intra and 
peritumoral vascularity (by the trichrome stain and CD34 
expression; a marker of  endothelial cells).
The expression of  VEGF (Figure 3I and L) and 
eNOS (Figure 3J and M) was determined as percent of  
positive cells (mean ± SD). Grafts of  AG treated animals 
expressed lower levels of  eNOS and VEGF than tumors 
of  control mice (9 ± 9 vs 75 ± 9, P < 0.01 and 25 ± 17 
vs 84 ± 9, P < 0.01, Mann Whitney test, respectively). 
Vascularity evaluated by the tr ichromic stain 
(Figure 3N) in xenografts of  untreated mice showed 
capillaries and medium size vessels in intratumoral areas, 
while medium and large size vessels were observed 
in peritumoral tissues. AG treatment did not modify 
peritumoral vascularity; however, a diminished level 
of  intratumoral vascularity was detected. As shown in 
Figure 3K and N, the intratumoral observations were 
confirmed by CD34 staining (6 ± 3 vs 21 ± 6, AG vs 
control, P < 0.05, Mann Whitney test), indicating an 
antiangiogenic effect of  AG.
Expression of  antioxidant enzymes: Reactive 
oxygen species (ROS), reactive nitrogen species (RNS) 
and redox state modulate cell proliferation, apoptosis 
and angiogenesis. Cells defend themselves against 
ROS mainly by antioxidant enzymes. In this way, 
superoxide dismutases convert superoxide radicals 
into hydrogen peroxide, which is in turn scavenged 
by catalase and GPx. According to their intracellular 
distribution, cytosolic CuZnSOD protects against 
cytosolic superoxide, while mitochondrial MnSOD 
decomposes mitochondrial-generated superoxide[19]. 
The four antioxidant enzymes were assessed in PANC-1 
xenografts. Tumors of  AG treated mice showed a lower 
expression (evaluated as percent of  positive cells; mean 
± SD) than grafts of  control animals, for CuZnSOD 
(14 ± 10 vs 80 ± 15), MnSOD (21 ± 12 vs 77 ± 17) and 
catalase (9 ± 6 vs 49 ± 12) (P < 0.01, Mann Whitney 
test). Meanwhile, GPx expression remained unchanged 
(70 ± 11 vs 81 ± 9, AG vs control).
DISCUSSION
The effect of  the NOS inhibitor aminoguanidine was 
studied in xenografts obtained by inoculation of  PANC-1 
human pancreatic ductal carcinoma cells into nude mice. 
In vivo results showed an antitumor effect of  AG, 
including suppression of  tumor growth, enhanced 
survival, delayed appearance of  metastases and a lower 
number of  homolateral metastases per animal. Similarly, 
tumor development diminished in a hamster model 
of  cholangiocarcinoma[11]. However, AG displayed an 
antimetastatic action on a model of  inflammation-
based murine fibrosarcoma progression, altering neither 
tumor incidence nor tumor growth[20]. Metastatic cell 
behavior could be positively or negatively regulated by 
nitric oxide, accordingly to iNOS and eNOS expression 
in endothelial cells, macrophages, stromal fibroblasts 
and cancer cells[21]. In an attempt to explain the observed 
B
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Figure 2  Action of AG on survival and metastases in PANC-1 xenografted 
mice. A: Time of spontaneous death of mice was determined, Kaplan-Meier 
survival curves were plotted and median survival was calculated. P < 0.01 for 
AG vs control, log-rank test; B: The development of palpable homolateral and 
contralateral metastases, which appeared mainly in lymph nodes, was checked 
until the death of the animals. Total number of metastases developed in both 
groups (n = 7 each group) and medians of appearance were determined. 
Curves were compared by logrank test, P < 0.01.
AG 2 mg/mL homolateral
AG 2 mg/mL contralateral
Control homolateral
Control contralateral
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in v i vo antitumor act ion of  AG, mult iple ex v i vo 
experiments were performed.
Tissues, both normal or abnormal, grow mostly by 
increasing the number of  cells. In turn, the cell number 
of  a given population is regulated by the balance between 
proliferation and death[22]. Altered indices of  proliferation 
and/or apoptosis could explain the diminished tumor 








Figure 3  Histopathology and immunohistochemistry of PANC-1 xenografted mice. Formalin fixed paraffin embedded tissue sections of control mice were 
stained with HE. A: Metastatic lymph node (× 400); B: Xenografts (× 630). Immunohistochemistry in control and AG treated mice. Tissue sections were stained with 
DAB and counterstained with hematoxylin; C: Formalin fixed paraffin embedded tissue sections of control mice were stained with trichromic solution (× 400); D, G: 
Ki-67 (× 630); E, H: Tunel (× 400); F, I: Bax (× 630); J, M: VEGF (× 630); K, N: eNOS (× 630); L, O: CD34 in control (× 400) and AG treated (× 630) mice. Formalin 
fixed paraffin embedded tissue sections of control mice were stained with trichrome solution.
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proliferation index, assessed by Ki-67 and PCNA 
expression, indicated that AG was antiproliferative in 
PANC-1 xenografts. Moreover, the apoptotic pathway 
state (evaluated by Bcl-2/Bax expression ratio) and 
apoptotic death (assayed by the Tunel assay) revealed an 
antiapoptotic action of  AG in pancreatic tumors. It has 
been hypothesized that Bcl-2 binds proapoptotic Bax to 
counteract its effects. Thus, the relative expression of  
Bcl-2 and Bax are involved in the regulation of  the cell 
death program. In this sense, AG treatment enhanced the 
Bcl-2/Bax ratio while diminishing the rate of  apoptosis. 
Therefore, AG did not lead to increased tumor cells 
apoptosis, but caused them not to proliferate. 
Many articles support the proapoptotic action of  
NO associated with iNOS induction and high NO 
levels[5], while others report a positive association 
between iNOS induction and tumor cell growth[11,23]. 
In a recent report[24], the in vivo and in vitro inhibition of  
hepatocellular carcinoma growth by AG was associated 
with a proapoptotic effect of  this drug. The cross-talk 
between NO and RAS/ERK and IKK/NF-kB pathways 
was determined to be crucial to this action. Conversely, 
our data show that the inhibition of  PANC-1 xenografts’ 
growth induced by AG is coupled to an antiapoptotic 
effect. It is well known that NO levels are quite different 
depending on the NOS isoform (eNOS or iNOS) 
involved in NO production. Although different NO 
concentrations regulate pathways related to either 
survival or cell death, the final effect on cell fate also 
depends on such factors as cell type, signaling pathways 
involved, genetic background and NO concentration 
in the microenvironment. Our in vitro experiments 
using PANC-1 cell line showed that the NO scavenger 
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide 
(PTIO) prevents cell proliferation (unpublished results). 
We have also demonstrated that activated ERK 1/2 
down-modulation is related to the in vitro inhibition of  
the proliferation of  PANC-1 cells[25]. Thus, even though 
a direct action of  the low levels of  NO produced by 
eNOS on this signal transduction pathway was not 
assessed in our work, it cannot be ruled out. 
Another potential contribution to in vivo tumor 
growth might be determined by interactions with stroma. 
Fibroblasts and inflammatory cells express iNOS and 
NO is related to cytokines and growth factors secretion. 
The iNOS inhibition in stromal cells by AG treatment 
might modulate neoplastic cells’ survival and death[26,27]. 
In addition, vascularity modulation is also involved in 
tumor growth. Locally, new blood vessel formation is 
essential for supplying oxygen and other nutrients to 
tumor cells and is one of  the altered manifestations that 
dictate metastatic tumor growth. It is well known that the 
VEGF-mediated angiogenesis requires NO production 
via eNOS in endothelial cells. Growing evidence 
supports the hypothesis that reciprocal relations between 
NO and VEGF might contribute to drive angiogenesis 
in pathophysiological conditions, depending on the 
amount of  produced NO[28]. Our results showed that 
AG reduced tumor vascularization and VEGF and 
eNOS expression in PANC-1 grafts. Small amounts of  
NO synthesized by eNOS are required for VEGF up-
regulation[28]. The low level of  NO produced by the 
AG-inhibited eNOS enzyme might induce the down-
modulation of  VEGF. In turn, VEGF down-regulation 
might hinder eNOS up-regulation, consistent with the 
reduced eNOS expression detected in PANC-1 grafts. 
Therefore, the antiangiogenic action of  AG could 
account for the reduced tumor growth rate, the lower 
rate of  metastasis and the delay in its appearance. 
Lastly, the expression of  CuZnSOD, MnSOD and 
catalase antioxidant enzymes was diminished by AG. The 
same effect on these enzymes was observed in diabetic 
rats[29] and on superoxide dismutases in doxorubicin 
treated rats[30]. GPx activity was slightly decreased after 
AG treatment in a model of  liver injury in rat[31]. Chronic 
treatment with AG might cause a disruption of  the 
cellular redox balance due to its capacity to scavenge 
oxidant reactive species[32] and to inhibit NO synthesis. 
This could explain the reduced expression of  antioxidant 
enzymes as a compensatory mechanism. Accordingly, our 
preliminary in vitro experiments in PANC-1 cells showed 
that hydrogen peroxide and NO intracellular levels were 
modified by AG, while cell proliferation was reduced. 
Cell cycle progression is modified by cellular redox status 
and the magnitude of  its imbalance might lead to cell 
proliferation, differentiation, growth arrest, apoptosis or 
necrosis[33]. Different cell lines require the pro-oxidant 
status to persist beyond the G1-S restriction point in the 
cell cycle[34,35]. The AG driven impaired production of  NO 
could hinder that oxidant level and, in turn, could prevent 
proliferation.
In conclusion, aminoguanidine, by exerting an 
antiapoptotic effect, shows an antitumoral action 
evidenced by a lower tumor volume at the end of  
treatment, a delayed appearance of  palpable metastases 
and an extended life span. The antiproliferative action 
is associated with a lower intratumoral Ki-67 content, 
an antiangiogenic effect, a reduced NO production and 
reduced expression of  antioxidant enzymes.
 COMMENTS
Background
Pancreatic cancer is a devastating disease because of its high mortality rate. 
Chemotherapy alone or combined with radiotherapy are poor attempts to 
overcome the illness. In cancer, the free radical nitric oxide exhibits both a 
cytotoxic and a cytoprotective effect according to its concentration within the 
tumor microenvironment. Although the in vitro action of nitric oxide synthase 
inhibitors (such as aminoguanidine) has been extensively studied in tumor cells, 
little research has been undertaken as regards their in vivo effects on cancer 
growth.
Research frontiers
Nitric oxide synthases catalyze the production of nitric oxide (NO), which, 
depending on its concentration, could act both as tumor promoter or suppressor. 
Compounds that modify expression and/or activity of these enzymes may be 
considered useful tools in cancer research.
Innovations and breakthroughs
The nitric oxide synthase (NOS) inhibitor aminoguanidine, by exerting an 
antiapoptotic effect, shows an antitumoral action evidenced by a lower tumor 
volume at the end of treatment, a delayed appearance of palpable metastases 
and an extended life span. The antiproliferative action is associated with a 
lower expression of endothelial NOS (eNOS) and antioxidant enzymes. 
Applications
Chemoresistance is still the major problem of anticancer drug treatment of 
malignant diseases such as pancreatic carcinoma. Aminoguanidine could 
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provide an attractive line of investigation as a multi-modal avenue due to its 
different effects on tumor biology.
Terminology
Nitric oxide is synthesized by a group of enzymes: the nitric oxide synthases. At 
least three isoforms have been described: eNOS, neuronal NOS (nNOS) and 
inducible NOS (iNOS). Most cancer cells express these enzymes and the NO 
produced is involved in biological processes associated with both survival and 
cell death.
Peer review
In this work, the authors have studied the action of the nitric oxide synthase 
inhibitor aminoguanidine (AG) in PANC-1 cells xenografts in relation to cell 
proliferation, apoptosis, angiogenesis and redox status. Interestingly, authors 
indicate that AG has strong effects on tumor progression, through inhibiting 
growth, apoptosis, vascularization and metastasis. This study will be of great 
interest to the carcinogenesis field, particularly in the design of new therapeutic 
drugs for pancreatic cancer.
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